Greywolf Therapeutics and Genomics Launch Strategic Relationship to Develop First‑in‑Class Treatments for Autoimmune Diseases

ERAPs (ERAP1 and ERAP2) are emerging therapeutic targets associated with multiple autoimmune diseases. Genomics will assemble the largest available genetic resource to evaluate how ERAP variants influence an individual's risk of developing multiple autoimmune diseases. Insights will be...